Breast cancer is one of the most common malignancies worldwide, and mutations in the PI3K/AKT/mTOR (PAM) signaling pathway ...

Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...

Breast cancer is the most common cancer among women, with over 2.3 million new cases diagnosed each year. Traditional ...

A model integrating deep learning with clinical and epidemiologic data may significantly improve lung cancer risk prediction based on LDCT screening.

In this episode of eSpeaks, Jennifer Margles, Director of Product Management at BMC Software, discusses the transition from traditional job scheduling to the era of the autonomous enterprise. eSpeaks’ ...

Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict five-year breast cancer risk from a routine screening mammogram. According to ...

Bottom Line: A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient’s risk of hepatocellular carcinoma (HCC), ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret prostate-specific antigen (PSA) test results compared to existing models.

Low-dose computed tomography (LDCT) screening is effective in reducing lung cancer mortality by detecting the disease at earlier, more treatable stages. However, high false-positive rates and the ...

CLAIRITY BREAST provides clinicians with a first-in-class, novel platform for identifying future risk of breast cancer CLAIRITY BREAST analyzes subtle imaging features on screening mammograms that ...